Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/593"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1043"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:content	"Drug Interactions ... In vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity."
dc:creator	"boycer"
dc:date	"09/24/2009 12:41:40"
rdfs:seeAlso	?:e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf

The resource appears as object in one triple:

{ modafinil_has_metabolite_modafinil-sulfone, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1043 }

Context graph